Adaptive Biotechnologies Corp vs United States Oil ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.07 (market cap $4.04B), while United States Oil ETF trades at $126.39. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | USO | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | — |
52-Week High | $25.45 | $152.96 |
52-Week Low | $12.30 | $66.17 |
Enterprise Value | $4.10B | — |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
USO is trading at $126.49, up 0.45% with bullish technical momentum as moving averages signal strength. The stock faces mixed sentiment amid ongoing Middle East supply disruptions and OPEC demand forecast revisions. Recent headlines highlight volatility from Hormuz tensions and shifting oil market dynamics.
Outlook remains volatile with supply risks supporting prices but demand concerns creating headwinds. Key resistance at $128-$132 and support at $123-$119 will dictate near-term direction. Geopolitical developments and inventory data remain critical catalysts for oil-linked equities.
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →